{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:07:00Z","timestamp":1761844020406},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2010,9,10]],"date-time":"2010-09-10T00:00:00Z","timestamp":1284076800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Adv Therapy"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1007\/s12325-010-0067-9","type":"journal-article","created":{"date-parts":[[2010,9,10]],"date-time":"2010-09-10T19:22:34Z","timestamp":1284146554000},"page":"774-784","source":"Crossref","is-referenced-by-count":9,"title":["The role of quetiapine extended release in the treatment of bipolar depression"],"prefix":"10.1007","volume":"27","author":[{"given":"Mario A.","family":"Cristancho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael E.","family":"Thase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,9,10]]},"reference":[{"key":"67_CR1","volume-title":"Manic-Depressive Insanity and Paranois","author":"E. Kraepelin","year":"1921","unstructured":"Kraepelin E. Manic-Depressive Insanity and Paranois. Manchester, NH: Ayer Company Publishers; 1921."},{"key":"67_CR2","volume-title":"Diagnostic and Statistical manual of Mental Disorders","author":"American Psychiatric Association","year":"2000","unstructured":"American Psychiatric Association: Diagnostic and Statistical manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.","edition":"Fourth Edition"},{"issue":"suppl.20","key":"67_CR3","first-page":"1","volume":"12","author":"P. Keck","year":"2007","unstructured":"Keck P, McIntyre R, Shelton R. Bipolar depression: best practices for the outpatient. CNS Spectr. 2007;12(suppl. 20):1\u201316.","journal-title":"CNS Spectr"},{"key":"67_CR4","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1001\/archpsyc.59.6.530","volume":"59","author":"L. Judd","year":"2002","unstructured":"Judd L, Akishal H, Schettler P, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59:530\u2013537.","journal-title":"Arch Gen Psychiatry"},{"key":"67_CR5","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1001\/archpsyc.60.3.261","volume":"60","author":"L. Judd","year":"2003","unstructured":"Judd L, Akishal H, Schettler P, et al. A prospective investigation of the natural history of the long term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry. 2003;60:261\u2013269.","journal-title":"Arch Gen Psychiatry"},{"key":"67_CR6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/NDT.S1162","volume":"4","author":"M. Thase","year":"2008","unstructured":"Thase M. Quetiapine monotherapy for bipolar depression. Neuropsych Dis Treat. 2008;4:21\u201331.","journal-title":"Neuropsych Dis Treat"},{"issue":"suppl.2","key":"67_CR7","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/j.euroneuro.2004.03.001","volume":"14","author":"R. Hirschfeld","year":"2004","unstructured":"Hirschfeld R. Bipolar depression: the real challenge. Eur Neuropsychopharmacol. 2004;14(suppl. 2):S83\u2013S88.","journal-title":"Eur Neuropsychopharmacol"},{"key":"67_CR8","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1001\/archpsyc.62.12.1322","volume":"62","author":"L. Judd","year":"2005","unstructured":"Judd L, Akishal H, Schettler P, et al. Psychosocial disability in the course of bipolar I and II disorder: a prospective, comparative, longitudinal study. Arch Gen Psychiatry. 2005;62:1322\u20131330.","journal-title":"Arch Gen Psychiatry"},{"key":"67_CR9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0165-1781(97)00109-1","volume":"73","author":"S. Disalver","year":"1997","unstructured":"Disalver S, Chen Y, Swann A, et al. Suicidality, panic disorder and psychosis in bipolar depression, depressive mania and pure mania. Psychiatry Res. 1997;73:47\u201356.","journal-title":"Psychiatry Res"},{"key":"67_CR10","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1399-5618.2005.00234.x","volume":"7","author":"A. Fagiolini","year":"2005","unstructured":"Fagiolini A, Frank E, Scott J, et al. Metabolic syndrome in bipolar disorder: findings from the bipolar disorders center for Pennsylvanians. Bipolar Disord. 2005;7:424\u2013430.","journal-title":"Bipolar Disord"},{"key":"67_CR11","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.1399-5618.2004.00137.x","volume":"5","author":"P. Mitchell","year":"2004","unstructured":"Mitchell P, Malhi G. Bipolar depression: phenomenological overview and clinical characteristics. Bipolar Disord. 2004;5:530\u2013539.","journal-title":"Bipolar Disord"},{"key":"67_CR12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1146\/annurev.clinpsy.2.022305.095301","volume":"4","author":"M. Thase","year":"2008","unstructured":"Thase M, Denko T. Pharmacotherapy of mood disorders. Annu Rev Clin Psychol. 2008;4:53\u201391.","journal-title":"Annu Rev Clin Psychol"},{"key":"67_CR13","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1176\/appi.ajp.162.7.1351","volume":"162","author":"J. Calabrese","year":"2005","unstructured":"Calabrese J, Keck P, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005;162:1351\u20131360.","journal-title":"Am J Psychiatry"},{"key":"67_CR14","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.4088\/JCP.v67n0703","volume":"67","author":"E. Brown","year":"2006","unstructured":"Brown E, McElroy S, Keck P, et al. A 7-week randomized, double-blind trial of olanzapine\/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry. 2006;67:1025\u20131033.","journal-title":"J Clin Psychiatry"},{"key":"67_CR15","doi-asserted-by":"crossref","first-page":"79","DOI":"10.4088\/JCP.v60n0203","volume":"60","author":"J. Calabrese","year":"1999","unstructured":"Calabrese J, Bowden C, Sachs G, et al. A double-blind placebo controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry. 1999;60:79\u201388.","journal-title":"J Clin Psychiatry"},{"key":"67_CR16","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.60.11.1079","volume":"11","author":"M. Tohen","year":"2003","unstructured":"Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine - fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003;11:1079\u20131088.","journal-title":"Arch Gen Psychiatry"},{"key":"67_CR17","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/01.jcp.0000248603.76231.b7","volume":"26","author":"M. Thase","year":"2006","unstructured":"Thase M, MacFadden W, Weisler R, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double blind, placebo controlled study (the BOLDER II study). J Clin Psychopharmacol. 2006;26:600\u2013609.","journal-title":"J Clin Psychopharmacol"},{"key":"67_CR18","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1080\/15622970701317265","volume":"9","author":"T. Suppes","year":"2008","unstructured":"Suppes T, Hirschfeld RM, Vieta E, et al. Quetiapine for the treatment of bipolar II depression: analysis of data from two randomized, double-blind, placebo-controlled studies. World J Biol Psychiatry. 2008;9:198\u2013211.","journal-title":"World J Biol Psychiatry"},{"key":"67_CR19","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jad.2009.10.007","volume":"121","author":"T. Suppes","year":"2010","unstructured":"Suppes T, Datto C, Minkwitz M, et al. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J Affect Dis. 2010;121:106\u2013115.","journal-title":"J Affect Dis"},{"key":"67_CR20","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.mehy.2005.01.036","volume":"65","author":"E.L. Altschuler","year":"2005","unstructured":"Altschuler EL, Kast RE. Using histamine (H1) antagonists, in particular atypical antipsychotics to treat anemia of chronic disease via interleukin-6 suppression. Med Hypoth. 2005;65:65\u201367.","journal-title":"Med Hypoth"},{"key":"67_CR21","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1176\/appi.ajp.161.12.2222","volume":"161","author":"N. Simon","year":"2004","unstructured":"Simon N, Otto M, Wisniewski S, et al. Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry. 2004;161:2222\u20132229.","journal-title":"Am J Psychiatry"},{"key":"67_CR22","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/01.jcp.0000138772.40515.70","volume":"24","author":"N. Simon","year":"2004","unstructured":"Simon N, Otto M, Weiss R, et al. Pharmacotherapy for bipolar disorder and comorbid conditions: baseline data from STEP-BD. J Clin Psychopharmacol. 2004;24:512\u2013520.","journal-title":"J Clin Psychopharmacol"},{"key":"67_CR23","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1749-6632.2001.tb05800.x","volume":"932","author":"J. Fawcett","year":"2001","unstructured":"Fawcett J. Treating impulsivity and anxiety in the suicidal patient. Ann NY Acad Sci. 2001;932:94\u2013102.","journal-title":"Ann NY Acad Sci"},{"key":"67_CR24","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1001\/archpsyc.59.10.905","volume":"59","author":"E. Frank","year":"2002","unstructured":"Frank E, Cyranowski J, Rucci P, et al. Clinical significance of lifetime panic spectrum symptoms in the treatment of patients with bipolar I disorder. Arch Gen Psychiatry. 2002;59:905\u2013911.","journal-title":"Arch Gen Psychiatry"},{"key":"67_CR25","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/da.20053","volume":"21","author":"B. Gaudiano","year":"2005","unstructured":"Gaudiano B, Miller I. Anxiety disorder comorbidity in bipolar I disorder: relationship to depression severity and treatment outcome. Depress Anxiety. 2005;21:71\u201377.","journal-title":"Depress Anxiety"},{"key":"67_CR26","doi-asserted-by":"crossref","first-page":"355","DOI":"10.4088\/JCP.v67n0304","volume":"67","author":"R.M. Hirschfeld","year":"2006","unstructured":"Hirschfeld RM, Weisler RH, Raines SR, et al. Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2006;67:355\u2013362.","journal-title":"J Clin Psychiatry"},{"key":"67_CR27","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1017\/S1461145709990423","volume":"13","author":"B. Bandelow","year":"2010","unstructured":"Bandelow B, Chouinard G, Bobes J, et al. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, doubleblind, placebo-and active-controlled study. Int J Neuropsychopharmacol. 2010;13:305\u2013320.","journal-title":"Int J Neuropsychopharmacol"},{"key":"67_CR28","doi-asserted-by":"crossref","first-page":"832","DOI":"10.4088\/JCP.v68n0603","volume":"68","author":"R. Kahn","year":"2007","unstructured":"Kahn R, Schulz C, Palazov V, et al. Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68:832\u2013842.","journal-title":"J Clin Psychiatry"},{"key":"67_CR29","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1017\/S1092852900020307","volume":"14","author":"R. Weisler","year":"2009","unstructured":"Weisler R, Joyce M, McGill L, et al. Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study. CNS Spectr. 2009;14:299\u2013313.","journal-title":"CNS Spectr"},{"key":"67_CR30","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.pnpbp.2008.09.026","volume":"33","author":"C. Figueroa","year":"2009","unstructured":"Figueroa C, Brecher M, Hamer-Maansson J, et al. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine inmediate release. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:199\u2013204.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"67_CR31","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/10673220500326425","volume":"13","author":"M. Thase","year":"2005","unstructured":"Thase M. Bipolar depression: issues in diagnosis and treatment. Harv Rev Psychiatry. 2005;13:257\u2013271.","journal-title":"Harv Rev Psychiatry"},{"key":"67_CR32","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1399-5618.2006.00432.x","volume":"8","author":"L. Yatham","year":"2006","unstructured":"Yatham L, Kennedy S, O\u2019Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord. 2006;8:721\u2013739.","journal-title":"Bipolar Disord"},{"key":"67_CR33","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1046\/j.1399-5618.2003.00067.x","volume":"5","author":"J. Golberg","year":"2003","unstructured":"Golberg J, Truman C. Antidepressant-induced mania: an overview of current controversies. Bipolar Disord. 2003;5:407\u2013420.","journal-title":"Bipolar Disord"},{"key":"67_CR34","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/hup.689","volume":"20","author":"E. Vieta","year":"2005","unstructured":"Vieta E. Mood stabilization in the treatment of bipolar disorder: focus on quetiapine. Hum Psychopharmacol. 2005;20:225\u2013236.","journal-title":"Hum Psychopharmacol"},{"key":"67_CR35","first-page":"3","volume":"4","author":"G. Sachs","year":"2005","unstructured":"Sachs G. What is a mood stabilizer? Clin Appr Bipolar Disorder. 2005;4:3.","journal-title":"Clin Appr Bipolar Disorder"},{"issue":"suppl.11","key":"67_CR36","first-page":"22","volume":"67","author":"C. Schneck","year":"2006","unstructured":"Schneck C. Treatment of rapid cycling bipolar disorder. J Clin Psychiatry. 2006;67(suppl. 11):22\u201327.","journal-title":"J Clin Psychiatry"},{"key":"67_CR37","unstructured":"Seroquel XR (quetiapine fumarate) extended-release tablets. Highlights of prescribing information. Available at: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/PediatricAdvisoryCommittee\/UCM191895.pdf . Accessed April 30, 2010."},{"key":"67_CR38","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1038\/sj.npp.1301646","volume":"33","author":"N.H. Jensen","year":"2008","unstructured":"Jensen NH, Rodriguiz RM, Caron MG, et al. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine\u2019s antidepressant activity. Neuropsychopharmacol. 2008;33:2303\u201323012.","journal-title":"Neuropsychopharmacol"},{"key":"67_CR39","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2147\/NDT.S4903","volume":"6","author":"R.K. Al Jurdi","year":"2010","unstructured":"Al Jurdi RK, Dixit LA, Sajatovic M. Role of extended release quetiapine in the management of bipolar disorders. Neuropsychiatr Dis Treat. 2010;6:29\u201335.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"67_CR40","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/sj.mp.4000586","volume":"4","author":"J. Licinio","year":"1999","unstructured":"Licinio J, Wong ML. The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol Psychiatry. 1999;4:317\u2013327.","journal-title":"Mol Psychiatry"},{"key":"67_CR41","doi-asserted-by":"crossref","first-page":"81","DOI":"10.4088\/JCP.v69n0111","volume":"69","author":"D. Mamo","year":"2008","unstructured":"Mamo D, Uchida H, Vitcu I, et al. Quetiapine extended-release versus immediate-release formulation: a positron emission tomography study. J Clin Psychiatry. 2008;69:81\u201386.","journal-title":"J Clin Psychiatry"},{"key":"67_CR42","doi-asserted-by":"crossref","first-page":"222","DOI":"10.4088\/JCP.v67n0208","volume":"67","author":"F. Gianfrancesco","year":"2006","unstructured":"Gianfrancesco F, Rajagopalan K, Sajatovic M, et al. Treatment adherence among patients with bipolar or manic disorder taking atypical and typical antipsychotics. J Clin Psychiatry. 2006;67:222\u2013232.","journal-title":"J Clin Psychiatry"},{"key":"67_CR43","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1136\/bmj.323.7314.647","volume":"323","author":"B. Bloom","year":"2001","unstructured":"Bloom B. Daily regimen and compliance with treatment. BMJ. 2001;323:647.","journal-title":"BMJ"},{"key":"67_CR44","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1185\/030079905X46340","volume":"21","author":"E. Vieta","year":"2005","unstructured":"Vieta E, Mullen J, Brecher M, et al. Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double blind, randomized, placebo-controlled studies. Curr Med Res Opin. 2005;21:923\u2013934.","journal-title":"Curr Med Res Opin"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-010-0067-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-010-0067-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-010-0067-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T07:55:58Z","timestamp":1559462158000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-010-0067-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,10]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["67"],"URL":"https:\/\/doi.org\/10.1007\/s12325-010-0067-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,10]]}}}